Preventing nausea and vomiting from antibody-drug conjugate treatment
Part of Digestive system clinical trials.
This trial tests two medications, fosrolapitant and palonosetron, to see if they can prevent nausea and vomiting caused by a type of cancer treatment called antibody-drug conjugates (ADCs). If you are about to start your first ADC treatment, this study might help you feel better during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with cancer.
- You have never received antibody-drug conjugate (ADC) treatment before and are about to start your first course.
- Your doctor expects you to live at least 3 more months.
- You are able to take care of yourself (ECOG performance status 0 or 1).
- Your bone marrow, kidneys, and liver are functioning adequately.
- If you are a woman who could become pregnant, you must have a negative pregnancy test before joining.
- You are willing and able to give written consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if two medicines given together, fosaprepitant and palonosetron, can prevent nausea and vomiting caused by strong chemotherapy given over several days. It's for people who have never had chemo before and are about to start a multi-day treatment for a solid tumor.
This study tests two medications (fosrolapitant and palonosetron) to prevent severe nausea and vomiting in patients with esophageal or lung cancer who are receiving chemotherapy combined with immunotherapy. If the medications work well, they could help patients feel better during treatment and complete their cancer care more comfortably.
This trial tests whether a combination of two anti-nausea drugs (fosrolapitant and palonosetron) can better prevent nausea and vomiting caused by Trastuzumab Rezetecan. If you are starting this cancer treatment, you may be able to join.
This trial studies whether palonosetron helps prevent nausea and vomiting caused by chemotherapy that has a moderate risk of vomiting. It may help you feel more comfortable during chemo and avoid treatment interruptions from severe nausea.
This study compares two anti-nausea medications, rolapitant and palonosetron, to see how well they prevent nausea and vomiting caused by chemoradiotherapy for lung cancer. It aims to help patients feel more comfortable during treatment.
This study is looking at whether a specific medication can help prevent or reduce nausea and vomiting caused by the breast cancer drug T-DXd (trastuzumab deruxtecan). If you are starting T-DXd for the first time, this study might help you manage those side effects.
Hear when a new Nausea and Vomiting Induced by Antibody-drug Conjugates (ADCs) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.